Alpha 2.0
Login Register
» Authors » Peter M Steijlen

Peter M Steijlen

Explore the profile of Peter M Steijlen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 61
Citations 1395
Followers 0
Related Specialties
Dermatology
Genetics
Molecular Biology
Top 10 Co-Authors
Michel van Geel
Maurice A M van Steensel
Klara Mosterd
Nicole W J Kelleners-Smeets
Patty J Nelemans
Jorge Frank
Valerie L R M Verstraeten
W H Irwin McLean
Antoni H Gostynski
Reno S Bladergroen
Published In
J Invest Dermatol
Eur J Dermatol
Am J Hum Genet
J Eur Acad Dermatol Venereol
Acta Derm Venereol
Affiliations
Soon will be listed here.
Recent Articles
1.
Exploring shared clinical features and successful therapeutic interventions in CARD14-associated papulosquamous eruption
Rossel S, Reich A, Baniel A, Wertheim-Tysarowska K, Frommherz L, Nolberczak D, et al.
J Eur Acad Dermatol Venereol . 2024 Nov; PMID: 39564931
No abstract available.
2.
The perceived quality of life in adult patients with inherited ichthyosis: a qualitative interview study
van Veen F, Rossel V, Rossel S, Steijlen P, Moser A, Veldman K, et al.
Br J Dermatol . 2024 Nov; 192(3):553-555. PMID: 39506357
No abstract available.
3.
Expanding phenotypic insights of palmoplantar keratodermas based on novel FAM83G variants
van Gisbergen M, Rossel S, Theunissen T, Janssen R, Kaseke T, van der Smagt J, et al.
Br J Dermatol . 2024 Oct; 192(3):544-546. PMID: 39449644
No abstract available.
4.
Long-term remission of Hailey-Hailey disease by Er:YAG ablative laser therapy
Debeuf M, Knoops K, Lopez-Iglesias C, Lookermans E, Nelemans P, Hamid M, et al.
J Eur Acad Dermatol Venereol . 2024 Oct; PMID: 39351702
Background: Hailey-Hailey disease (HHD) is a rare genetic therapy-resistant blistering disease with great disease burden. Treatment is currently focused on symptomatic relief. Er:YAG ablative laser therapy is a therapeutic modality...
5.
Late-onset Morbus Hailey-Hailey
Debeuf M, Verkouteren B, Gostynski A, Hamid M, van Geel M, Steijlen P, et al.
Eur J Dermatol . 2024 Jun; 34(2):218-219. PMID: 38907562
No abstract available.
6.
Effectiveness of a patient decision aid for patients with superficial basal cell carcinoma: A pre- and post-implementation study
van Delft L, Essers B, Nelemans P, Mosterd K, van Winden M, Romaen I, et al.
Patient Educ Couns . 2023 Jul; 115:107907. PMID: 37487347
Objective: This study evaluates whether using a patient decision aid (PDA) for patients with superficial basal-cell carcinoma (sBCC) results in a decreased decisional conflict level and increased knowledge. Methods: In...
7.
Palmoplantar keratoderma as a clinical feature of pathogenic variants in the filaggrin gene
Clabbers J, Bolling M, Burms C, Vreeburg M, Lemmink H, van den Akker P, et al.
J Eur Acad Dermatol Venereol . 2022 Oct; 37(4):e486-e490. PMID: 36308042
No abstract available.
8.
STS pathogenic variants in a Dutch patient cohort clinically suspected for X-linked ichthyosis show genetic heterogeneity
Nagtzaam I, van Leersum F, Kouwenberg L, Blok M, Vreeburg M, Steijlen P, et al.
Br J Dermatol . 2022 Jul; 187(5):820-822. PMID: 35822528
No abstract available.
9.
Reorganising dermatology care: predictors of the substitution of secondary care with primary care
van den Bogaart E, Kroese M, Spreeuwenberg M, Martens H, Steijlen P, Ruwaard D
BMC Health Serv Res . 2020 Jun; 20(1):510. PMID: 32503509
Background: The substitution of healthcare is a way to control rising healthcare costs. The Primary Care Plus (PC+) intervention of the Dutch 'Blue Care' pioneer site aims to achieve this...
10.
Sjögren-Larsson syndrome: The mild end of the phenotypic spectrum
Staps P, van Gaalen J, van Domburg P, Steijlen P, Ferdinandusse S, den Heijer T, et al.
JIMD Rep . 2020 May; 53(1):61-70. PMID: 32395410
Sjögren-Larsson syndrome (SLS) is a rare inborn error of lipid metabolism. The syndrome is caused by mutations in the gene, resulting in a deficiency of fatty aldehyde dehydrogenase. Most patients...